Once again, FDA had the privilege of attending the 2013 DiabetesMine Innovation Summit this past November. This was another great opportunity for us to share current FDA regulatory perspectives with the diabetes community and to update attendees on many of FDA’s ongoing efforts related to diabetes.
A recent RCT set out to determine the safety and tolerability of ipragliflozin in combination with metformin on lowering glucose in patients with type 2 diabetes. The study also looked at the pharmacokinetic (PK) properties of metformin.
The updated recommendations are in response to a previous published article on aspirin therapy released in 2011. The current 2013 guideline recommendations by the ADA suggest aspirin therapy for primary prevention in patients with either type 1 or 2 diabetes who have an increased risk of cardiovascular disease.
Adding bolus insulin to meals is a big deal for many people. You finally adjusted to taking one injection at night, but having to take three more injections during the day sounds like a real hassle.
A Montreal research team led by Jennifer Estall at the IRCM discovered that a protein found in muscle tissue may contribute to the development of type 2 diabetes later in life. The study’s results, published in the printed edition of the scientific journal American Journal of Physiology – Endocrinology and Metabolism, indicate that the protein […]
A retrospective review was conducted for all patients that have undergone bariatric surgery between January 2004 and December 2007 at the Cleveland Clinic Bariatric and Metabolic Institute. These patients had type 2 diabetes prior to the operation, and have had at least 5 years of follow-up.
Revealing their prototype, which has been in the works for the past 18 months, Google X lab members and project co-founders Brian Otis and Babak Parviz write through their company blog that many of they people they have talked to “say managing their diabetes is like having a part-time job.”
The findings come from a study that tracked the health of nearly 100,000 US nurses over a period of eight years. Lifting weights, doing press-ups or similar resistance exercises to give the muscles a workout was linked with a lower risk of diabetes, the work in PLoS Medicine shows.
More than half of adults with type 2 diabetes who are at risk of vision loss from their condition have not been advised by their doctors of the danger.
Contrary to a common belief, researchers have shown that genetic regions associated with increased risk of type 2 diabetes were unlikely to have been beneficial to people at stages through human evolution.
SGLT2 inhibitors act by blocking the kidneys’ reabsorption of sugar, or glucose. The result is that more glucose is released in the urine and the patient’s blood glucose level goes down — a major goal of diabetes treatment.
Farxiga is a once-a-day tablet designed to help diabetes patients eliminate excess sugar via their urine. That differs from older drugs that decrease the amount of sugar absorbed from food and stored in the liver.
DPP-4 inhibitors, such as Januvia and Onglyza, now account for 21 percent of treatments. Long-acting insulins, such as Lantus and Levemir, also saw an increase from nearly negligible in 1997 to 18 percent in 2012. Short-acting insulins, like Novolog, Humalog, and Apidra, have increased modestly.
Chronic wounds are a global problem, the researchers say. In addition to obesity and diabetes worldwide, skin ulcers occur as a consequence of neurological problems, rheumatological illnesses, blood vessel inflammation and infection.
Previously it was thought to only affect people with type 1 diabetes, but in a recent study that examined data from the past 30 years, researchers determined that the dawn phenomenon occurred frequently among patients with type 2 diabetes.
A chemical naturally occurring in the body, already proven to produce a feeling of being full when administered, has found an effective new route via a spray on the tongue, say health researchers from the University of Florida.
People with type 2 diabetes who use insulin to help control elevated blood sugar might be able to end their dependence on it if new research progresses.
Which is better, adding medications one at a time or all at once? It’s a question physicians will be pondering as they discuss the results of an ongoing study into how to dose oral medications for people with type 2 diabetes.
When looking at progression, the FIELD study observed fundus photographs taken over 5 years which showed that taking fenofibrate decreased 2-step progression by 79% in patients with existing DR prior to the study.
Why is Metformin considered the “starter” medicine for people who have been newly diagnosed with diabetes? Here are some of the benefits of this drug.